Case observations reveal late-onset pentosan polysulfate maculopathy, suggesting updates to management guidelines.
These cases suggest that late development of clinically detectable pentosan polysulfate maculopathy may occur years after drug cessation. These findings corroborate earlier work suggesting that choroidal changes may be an early but nonspecific sign of toxicity. This observation has important ramifications for PPS dosing and surveillance guidelines.
No takes yet. Share an insight, caveat, or question.
N’jai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: